Secreted VEGF‐D, a critical biochemical biomarker used in the diagnosis of LAM, was detected in the supernatant of both WT and TSC2−/− cultures and was insensitive to acute rapamycin treatment (Figure 1B). This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.